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AbstrACt
Intratumoral delivery of viruses and virus- associated 
molecular patterns can achieve antitumor effects that are 
largely mediated by the elicitation or potentiation of immune 
responses against the malignancy. Attenuated vaccines are 
approved and marketed as good manufactiring practice 
(GMP)- manufactured agents whose administration might 
be able to induce such effects. Recent reports in mouse 
transplantable tumor models indicate that the rotavirus, 
influenza and yellow fever vaccines can be especially 
suitable to elicit powerful antitumor immunity against cancer 
following intratumoral administration. These results highlight 
that intratumoral anti- infectious vaccines can turn cold 
tumors into hot, and underscore the key role played by virus- 
induced type I interferon pathways to overcome resistance to 
immune checkpoint- targeted antibodies.
From Coley’s clinical experiments with local 
treatment with bacteria or bacteria toxins1 to 
the generalized use of bacillusof Calmette and 
Guerin (BCG) for superficial bladder cancer,1 
multiple lines of evidence suggest that local 
instigation of infectious micro- organisms or 
synthetic molecules mimicking their compo-
nents, the so- called pathogen- associated 
molecular patterns (PAMPs) acting as pattern 
recognition receptor agonists (PRRs), can be 
beneficial against cancers.2
In the case of viruses, multiple attempts have 
been made to focus cytopathic effects against 
cancer, using the so- termed oncolytic viruses. 
Mounting evidence indicates that replication- 
competent oncolytic viruses and replication- 
defective viral vectors exert their therapeutic 
effects mainly as a result of more potent anti-
tumor immune responses.3 Such efficacy can 
be augmented when the genome of the virus is 
armed with genes that enhance immunity, such 
as cytokines and costimulatory factors.3
Intratumoral engineered variants of adeno-
virus, vaccinia virus, herpes simplex 1 virus 
(HSV), Newcastle disease virus and reovirus 
have shown remarkable activity in preclinical 
models and have progressed or are progressing 
to the clinic. The most advanced agent of this 
kind is T- vec (Talimogene laherparepvec), 
an attenuated HSV engineered to encode 
granulocyte- macrophage colony- stimulating 
factor (GM-CSF) which is approved for intra-
tumoral infection in advanced melanoma4 
and which seems to render synergistic effects 
if combined with systemic treatment with anti- 
cytotoxic T- lymphocyte antigen 4 (CTLA-4)5 
or anti- programmed death- ligand 1 (PD1)6 
monoclonal antibodies as immune check-
point inhibitors.
In essence, the main factors that determine 
the antitumor effect are believed to be due 
to (1) immunogenic tumor cell death that 
releases antigens that can be presented by 
dendritic cells (especially cDC1 cells) and 
presentation of immunostimulatory mole-
cules (calreticulin membrane expression, ATP 
release in the tumor microenvironment)7; 
(2) presence of moieties that are recognized 
by innate receptors of the immune system, 
triggering maturation of dendritic cells and 
causing local inflammation notably via type 
I interferon secretion7; and (3) recruitment 
and activation of antitumor T cells.7
In this scenario our group set out to iden-
tify routinely used attenuated viral vaccines 
that could be used via the intratumoral route. 
The advantage of repurposing such approved 
and marketed agents is that clinical devel-
opment would be much simplified based on 
solid safety records.
Rotavirus infection is a serious threat causing 
severe diarrhea in infants. Attenuated vaccines 
are protective when orally given. These 
commercially available double- stranded RNA 
(dsRNA) viral attenuated strains turned out to 
be very potent stimulators of the nuclear factor 
kappa- light- chain- enhancer of activated B cells 
(NFκΒ) and type I interferon pathways. Inter-
estingly, this stimulation is independent from 
the innate Toll- like immune receptors but 
dependent on another PRRs known as retinoic 
acid induced gene 1 (RIG- I), which is able to 
detect intracytoplasmic dsRNA.8 Furthermore, 
rotavirus exerts cytopathic effects, killing a 
2 Melero I, et al. J Immunother Cancer 2020;8:e000443. doi:10.1136/jitc-2019-000443
Open access 
variety of both adult and pediatric cancer cell lines in culture 
with features of immunogenic cell death (ATP release).7 
Interestingly, if given intratumorally to mouse bearing trans-
plantable tumors, including pediatric syngeneic neuroblas-
toma murine models, remarkable local therapeutic effects 
are elicited that are dependent on natural killer cells (NK), 
CD4 and CD8 T cell immunity. Most importantly, in murine 
models that are refractory to immune checkpoint- targeted 
therapies, intratumoral rotavirus is able to synergize and 
overcome resistance to anti- CTLA-4 or anti- PD- L1 mono-
clonal antibodies, including against tumor lesions growing 
subcutaneously on the contralateral uninjected flank 
(anenestic effect).9 It is of important note that prevaccina-
tion of mice prior such intratumoral virotherapy does not 
spoil efficacy.
In the same line, the yellow fever vaccine strain 17D used 
for travelers and dwellers in endemic areas is also cyto-
pathic for a large panel of human and mouse tumor cell 
lines, and intratumor administration clearly delays tumor 
progression in a manner mediated by CD8 T cell immunity 
with some measurable effect against non- injected concomi-
tant tumors.10 Very importantly, efficacy was potentiated by 
previous vaccination against the virus in a manner depen-
dent on T cell antiviral immunity. In this case additive 
effects with systemic immunostimulatory monoclonal anti-
bodies directed to anti- PD1 or anti- CD137 were found.
Similarly, Newman et al reported that intratumoral injec-
tions of anti- influenza vaccines could also elicit immune- 
mediated antitumor activity in an aggressive melanoma 
syngeneic transplantable tumor model (Proceedings of 
the National Academy of Sciences (PNAS), in press). 
Similar to the rotavirus observation, inactivated influenza 
virus was sufficient to show activity against tumors on 
intratumoral administration. However, and most surpris-
ingly, only unadjuvanted inactivated influenza vaccines 
were able to generate such antitumor efficacy. Indeed, 
squalene- based adjuvanted influenza vaccines were losing 
their antitumor activity because adjuvants were recruiting 
interleukin-10- secreting B regulatory cells.
Importantly, for none of these three strategies, pre- 
existing immunization against the corresponding 
pathogen/vaccine did preclude the antitumor efficacy of 
its intratumoral delivery.
It is to be considered that while 17D yellow fever and 
influenza vaccines are approved for injected routes of 
administration, rotavirus vaccines are only approved for 
oral administration. However, because rotavirus vaccines 
have mostly polysaccharides as adjuvants, they should, like 
for yellow fever and influenza vaccines, be amenable to a 
rapid clinical translation for in situ virus- vaccine cancer 
immunotherapy.
All considered, these new studies open the field for 
repurposing viral vaccines in strategies combining local 
virotherapy and other immunotherapy agents (figure 1). 
This is not at odds with intratumoral compounds based 
on viral immunity such as Toll- like receptor (TLR3, 
TLR9) or stimulator of interferon genes protein (STING) 
agonists that are being developed for intratumoral admin-
istration.1 2 In any case, it is clear that what best mimics a 
local viral infection is the virus itself. These agents have a 
number of pros and cons if compared with the preclini-
cally studied repurposed vaccines. Prevaccination is prob-
ably an interesting safety feature that seems to increase 
efficacy or that at least does not spoil it. Another question 
that can only be addressed in humans is the prime- boosting 
effect of injecting multiple tumor lesions at different time 
points within the same patient. Such strategy could better 
address the cancer heterogeneity existing within metastatic 
patients while amplifying pre- existing anticancer immune 
responses. Also, these intratumoral virus vaccines could be 
Figure 1 Repurposing anti- infectious viral vaccines for intratumoral immunotherapy to turn cold tumors into hot and overcome 
resistance to immune checkpoint- targeted therapies.
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of great value to trigger the antitumor immunity in a neoad-
juvant setting in order to avoid postsurgery relapses. Last 
but not least, these commercially available and pediatric- 
grade anti- infectious vaccines could be of interest to treat 
cancers arising in infants and children, or any other rare 
tumor indication which is not frequent enough to benefit 
from registration trials of pattern recognition receptor 
agonists and oncolytic viruses.
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